primary sclerosing cholangitis

Cilofexor Did Not Prevent Fibrosis Progression in Non‑Cirrhotic Primary Sclerosing Cholangitis: Results from the PRIMIS Phase 3 Trial

By MedXY 11/09/2025

The phase 3 PRIMIS trial found cilofexor 100 mg once daily did not reduce histological fibrosis progression at 96 weeks in non‑cirrhotic primary sclerosing cholangitis; pruritus was more frequent with cilofexor.

Gastroenterology news

Elafibranor Shows Promise as a Safe and Effective Therapy for Primary Sclerosing Cholangitis: Insights from the Phase II ELMWOOD Trial

By MedXY 10/29/2025

The phase II ELMWOOD trial demonstrates that elafibranor, a dual PPAR-α/δ agonist, is well tolerated and significantly improves biochemical markers in patients with primary sclerosing cholangitis over 12 weeks, warranting further investigation.

Gastroenterology Internal Medicine news

Bexotegrast in Primary Sclerosing Cholangitis: Promising Safety and Pharmacodynamics from Phase II INTEGRIS-PSC Trial

By MedXY 10/28/2025

The Phase II INTEGRIS-PSC trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, is well tolerated in PSC patients with liver fibrosis and shows potential to attenuate fibrotic progression, supporting integrin-targeted therapy as a novel approach.

Gastroenterology news Specialties

Primary Sclerosing Cholangitis in a 45-Year-Old Male: A Case Report

By MedXY 10/02/2025

A 45-year-old male presents with cholestatic liver enzyme elevation and pruritus, diagnosed with primary sclerosing cholangitis confirmed by imaging and liver biopsy. Clinical management and prognosis are discussed.